Compare Genworth Financial Inc Common Stock (GNW) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genworth Financial Inc Common Stock vs Zoetis Inc — how do they compare? Genworth Financial Inc Common Stock trades at $8.82 (market cap $3.33B), while Zoetis Inc trades at $76.07 (market cap $31.11B). The key difference: Zoetis Inc is far larger — about 9.3× Genworth Financial Inc Common Stock's market cap, and Zoetis Inc pays a 2.82% dividend while Genworth Financial Inc Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genworth Financial Inc Common Stock for 0 Days and Zoetis Inc for 71 Days on average.
| GNW | ZTS | |
|---|---|---|
Market Cap | $3.33B | $31.11B |
Volume | 3,324,561 | 2,515,954 |
Sector | Financials | Health |
52-Week High | $10.60 | $147.53 |
52-Week Low | $7.94 | $69.09 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $2.85B | $38.68B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Genworth Financial (GNW) trades at $8.89, down 1.77% today, with neutral technical signals and mixed fundamental performance. The company maintains stable revenue around $7.1-7.2B but faces margin pressure, with net income declining from $223M to $212M year-over-year. Recent Q2 2026 earnings beat expectations at $0.29 EPS, while the company expanded its share repurchase program by $500M in September 2026.
GNW presents value characteristics with low P/B (0.38) and P/S (0.49) ratios, but weak profitability metrics (ROE 2.42%) and analyst caution (70.59% hold rating) suggest limited near-term catalysts. Key risks include legacy insurance liabilities and competitive pressures, while the upcoming Q3 earnings on November 4 could provide directional clarity.
Zoetis (ZTS) trades at $74.3, down 1.78% on the day, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a net income margin of 27.69% and ROE of 64.91% for 2025, though recent quarterly earnings have been mixed. Revenue growth has been steady, reaching $9.47B in 2025, while valuation ratios like P/E of 12.28 suggest potential undervaluation relative to historical levels. Recent news highlights competitive pressures in the U.S. companion animal market but also underscores Zoetis's resilient margins.
The outlook for ZTS is cautiously optimistic, with a consensus price target of $87.33 implying significant upside. Key opportunities include its industry-leading margins and international growth, while risks involve heightened competition and weak U.S. pet care demand. Analyst sentiment is balanced with 46.88% buy ratings, but investors should monitor Q3 2026 earnings for confirmation of a turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Genworth Financial Inc Common Stock
Genworth Financial, Inc. is a holding company that provides products and services related to aging and long-term care planning, and is the parent company of publicly traded mortgage insurer Enact Holdings, Inc.
Read more on GNW →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
